Analysis for IVZ

📈 Growth & Financial Trajectory

Over 7 quarters, Revenues rose from about $1.593B in 2024 Q3 to $1.826B in 2026 Q2, ~14% growth. Net income attributable to parent swung from a trough of about -$1.37B in 2025 Q3 to +$0.38B in 2026 Q2, signaling a material earnings turnaround despite quarterly volatility. The trajectory shows improving scale and earnings power, though late-2025 results intermittently muted profitability.

💰 Margins & Cash Flow

Operating metrics reflect mid-teens to ~20% margins in several quarters (e.g., 333.2M operating income on 1.640B revenue in 2025 Q3 ≈ 20%). 2025 Q4 was a sharp negative operating result, then 2026 Q2 regained positive operating income. Net cash flow from operating activities remained solid in multiple quarters (606.2M in 2025 Q3; 734.2M in 2026 Q2 continuing). Cash flow from investing was consistently negative, and financing activity swung, resulting in a modest overall cash flow in some periods.

🛡️ Balance Sheet & Liquidity

Total Assets run around $26.8–28.0B with Equity of about $14.3–15.0B. Long-term debt remains modest (≈$1.9–$2.1B), supporting a healthy balance sheet. Current liabilities run roughly $13.6–14.1B, yielding a robust liquidity profile (current assets ~2x current liabilities in several quarters).

⚠️ Key Drivers & Risks

• Drivers: Asset-management demand and diversified product mix (ETFs, fixed income) support volume and fee-related revenue.
• Risks: Earnings volatility tied to market cycles and tax effects; potential valuation sensitivity to flow changes and regulatory/interest-rate shifts.